← 返回列表Company仁川创业园区 is the first space in 韩国 where the public and private sectors collaborate to nurture 初创企业s. It consists of InSta I, operated by a public institution (仁川科技园), and InSta II, operated by a private company (新韩金融集团). Here, we introduce the representative resident companies of InSta I.
These 初创企业s have been recognized for the future value of their products and the growth potential of their companies, having been selected for 韩国's highest-level 初创企业 preferential programs, and they are spreading their wings wide to leap toward becoming '独角兽企业' — 初创企业s valued at over USD 1 billion.
RudaCure Inc. (CEO Yongho Kim), which leverages basic biomedical research to present a new paradigm in 新药开发 capable of achieving fundamental treatment for intractable conditions, is working on developing a 干眼症治疗药 without 副作用 and a non-addictive 疼痛治疗药.
Focusing on the market for age-related eye diseases, the company has gained attention for developing and 专利ing 滴眼液 for treating 眼部 conditions such as 干眼症. ← 返回列表
谁将成为未来的独角兽企业？仁川创业园区铺路前行
2021-07-16
These 初创企业s have been recognized for the future value of their products and the growth potential of their companies, having been selected for 韩国's highest-level 初创企业 preferential programs, and they are spreading their wings wide to leap toward becoming '独角兽企业' — 初创企业s valued at over USD 1 billion.
RudaCure Inc. (CEO Yongho Kim), which leverages basic biomedical research to present a new paradigm in 新药开发 capable of achieving fundamental treatment for intractable conditions, is working on developing a 干眼症治疗药 without 副作用 and a non-addictive 疼痛治疗药.
Focusing on the market for age-related eye diseases, the company has gained attention for developing and 专利ing 滴眼液 for treating 眼部 conditions such as 干眼症.